NH TherAguix: NH TherAguix SAS : Nature's Scientific Reports publishes an article describing the quantification of novel radio-enhancer AGuIX developed in brain metastases

Press Release: NH TherAguix : NH TherAguix receives FDA Fast Track designation

NH TherAguix: NH TherAguix SAS : announces the publication of promising preclinical results of AGuIX in combination with targeted radioligand therapies (TRT)

NH TherAguix: NH TherAguix SA: Successful completion of recruitment in NANORAD 2, a Phase 2 Clinical Trial of AGuIX with whole brain radiation therapy in brain metastasis

NH TherAguix: NH TherAguix SAS : appoints Vincent Carrre as Chief Executive Officer

NH TherAguix: NH TherAguix SAS : announces the arrival of Aurlien Meyzaud as Head of Intellectual Property and Business Intelligence

NH TherAguix: NhTherAguix : NH THERAGUIX announces the enrolment in Boston of the 2 first patients in its clinical trials NANOBRAINMETS Phase II targeting brain metastasis and NANOSMART Phase Ib/II targeting pancrea